Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched the novel fixed-dose combination (FDC) drug – Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.
Alok Malik, Group Vice-President & Head, India Formulations, Glenmark Pharmaceuticals Limited, said, “We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”
Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist, and Mometasone Furoate, an inhaled corticosteroid that is approved by the DCGI (Drug Controller General of India).